Astrana Health vs Chemed
Astrana Health is the larger business, with $3.18bn of revenue in fiscal 2025 against $2.53bn for Chemed (1.3 times as much). Astrana Health grew faster (56.4% against 4.1%). Chemed kept more of each dollar of sales as profit: a net margin of 10.5% against 0.7%. Chemed carries less debt relative to equity (0.0% against 135.0%).
| Latest fiscal year | Astrana HealthASTH, 2025 | ChemedCHE, 2025 |
|---|---|---|
| Revenue | $3.18bn | $2.53bn |
| Revenue growth | 56.4% | 4.1% |
| Net income | $22.5m | $265m |
| Operating margin | 2.5% | 13.4% |
| Net margin | 0.7% | 10.5% |
| Return on equity | 3.0% | 25.3% |
| Free cash flow | $104m | $325m |
| Cash | $429m | $74.5m |
| Total debt | $1.05bn | $0 |
| Debt to equity | 135.0% | 0.0% |
| Dividend per share | — | $2.20 |
| Dividend yield | 0.1% | 0.5% |
| Share buybacks | $25.6m | $432m |
| Employees | 3,000 | 15,811 |
| Market value | $1.78bn | $7.03bn |
| Price vs our value range | Below our value range | Within our value range |
| Moat score | 36 (Weak) | 68 (Moderate) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 13 sales |